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p38 MAPK activation through B7-
H3-mediated DUSP10 repression 
promotes chemoresistance
Karine Flem-Karlsen  1,2, Christina Tekle1, Tove Øyjord1, Vivi A. Flørenes3, 
Gunhild M. Mælandsmo1,4, Øystein Fodstad1,2 & Caroline E. Nunes-Xavier1
Immunoregulatory protein B7-H3 is involved in the oncogenic and metastatic potential of cancer 
cells, as well as in drug resistance. Resistance to conventional chemotherapy is an important aspect of 
melanoma treatment, and a better understanding of how B7-H3 enhances drug resistance may lead 
to the development of more effective therapies. We investigated the in vitro and in vivo sensitivity of 
chemotherapeutic agents dacarbazine (DTIC) and cisplatin in sensitive and drug resistant melanoma 
cells with knockdown expression of B7-H3. We found that knockdown of B7-H3 increased in vitro and 
in vivo sensitivity of melanoma cells to the chemotherapeutic agents dacarbazine (DTIC) and cisplatin, 
in parallel with a decrease in p38 MAPK phosphorylation. Importantly, in B7-H3 knockdown cells we 
observed an increase in the expression of dual-specific MAP kinase phosphatase (MKP) DUSP10, a 
MKP known to dephosphorylate and inactivate p38 MAPK. DUSP10 knockdown by siRNA resulted 
in a reversion of the increased DTIC-sensitivity seen in B7-H3 knockdown cells. Our findings highlight 
the potential therapeutic benefit of combining chemotherapy with B7-H3 inhibition, and indicate that 
B7-H3 mediated chemoresistance in melanoma cells is driven through a mechanism involving DUSP10-
mediated inactivation of p38 MAPK.
B7-H3, a member of the B7 family of immune checkpoint proteins, is upregulated in many different cancer types1, 
and B7-H3 targeted therapy is currently being tested in several clinical trials2. B7-H3 has been found to favor 
tumor growth, cell proliferation, migration, invasion, and drug resistance3–5, although many aspects regarding 
its oncogenic potential are still unknown. For instance, B7-H3 has been involved in various signal transduction 
pathways, including the JAK/STAT, PI3K/Akt, and the mitogen activated protein kinase (MAPK) Raf/MEK/ERK 
pathways2, but their relation with chemoresistance is not fully understood.
The MAPK pathways regulate various cellular processes, such as proliferation, differentiation, apoptosis and 
stress responses, and include four major pathways, as defined by their MAPK effector: ERK1/2, ERK5, JNKs and 
p38s MAPK6. The p38 MAPK pathway is mainly activated by stress signals such as UV light, osmotic shock and 
cytokines7. When activated, the p38 MAPK pathway can phosphorylate a wide range of proteins. This include 
activating phosphorylation of various transcription factors that may, amongst many physiological processes, lead 
to the maintenance of a tumor aggressive phenotype and/or resistance to chemotherapy8.
The MAPKs are activated by phosphorylation by upstream kinases and inactivated by dephosphorylation 
of a group of dual specificity phosphatases called MAP kinase phosphatases (MKPs). MKPs include 10 active 
enzymes that show different specificity towards subgroups of MAPKs and have different localization patterns 
which permits a tight regulation, spatially and temporally, of the MAPK signaling. The MKPs can be divided into 
three groups: 1) the nuclear MKPs DUSP1, DUSP4, DUSP2, and DUSP5; 2) the cytoplasmic, ERK1/2-specific 
MKPs DUSP6, DUSP9, and DUSP7; and 3) the stress-activated, p38/JNK-specific MKPs: DUSP8, DUSP10, and 
DUSP169.
Melanomas have classically been treated with chemotherapy, including DNA alkylating, platinum-based, 
and microtubule-interacting agents10. However, low response rates, high toxicity and resistance are commonly 
found11. In the past years, therapies with small-molecule inhibitors or antibodies targeting immune checkpoint 
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proteins or BRAF have become more prominent12, but treatment resistance is frequent13. Despite the recent 
advances in melanoma treatment, dacarbazine (DTIC) chemotherapy is still being widely used even though its 
response rate as a single agent is only 10–20%14,15. Thus, improvement in melanoma therapy is highly needed. 
DTIC treatment combined with targeted therapy may improve the overall response, and is a promising way for-
ward for treatment of metastatic melanoma16.
Inhibiting expression of B7-H3 has been found to increase cell and tumor sensitivity to various chemothera-
peutic agents4,17–21. In this study, we investigated the mechanism behind B7-H3 mediated resistance to DTIC and 
cisplatin, using melanoma as a model. We identified modulation of p38 MAPK activation by DUSP10 as a novel 
mechanism of B7-H3-mediated chemoresistance.
Results
Reduced B7-H3 expression increases in vitro and in vivo sensitivity of melanoma cells to 
chemotherapy. We have previously observed in in vitro proliferation assays that cells with decreased expres-
sion of B7-H3 display increased sensitivity to DTIC and small anti-cancer drugs, including molecular inhibitors4. 
However, the mechanism by which B7-H3 induces resistance to therapy is still unknown. To determine if the 
B7-H3 associated drug resistance might involve effects asserted by stress signaling, we treated melanoma cells 
with two chemotherapeutic agents, DTIC and cisplatin. The melanoma cell lines FEMX-I and MDA-MB-435 had 
stably reduced B7-H3 expression by short hairpin RNA (shRNA), as previously described (Fig. 1A; and in refer-
ence5). Diminished B7-H3 protein expression reduced the colony-formation ability of the cells upon treatment 
with both DTIC and cisplatin (Fig. 1B,C). This effect was also observed in vivo utilizing nude mice. Subcutaneous 
injection of cells with knocked down B7-H3 expression led to decreased relative tumor volume compared to 
control cells (Fig. 2A,B), and was further decreased when the mice were subjected to DTIC treatment (Fig. 2A). 
Of the DTIC treated mice 6/10 animals had regrowth at 100 days, while tumors in mice injected with B7-H3 
knockdown cells showed regrowth in only 1/11 animals (Fig. 2A). Thus, melanoma cells with low expression of 
B7-H3 are more sensitive to DTIC and cisplatin chemotherapy.
Figure 1. Melanoma cells with decreased B7-H3 expression have increased sensitivity to dacarbazine (DTIC) 
and cisplatin chemotherapy. (A) Immunoblot verifying the lentiviral knockdown of B7-H3 in MDA-MB-435 
and FEMX-I cells. In cells were B7-H3 expression was decreased (short hairpin B7-H3, shB7-H3), the 
ability to form colonies in response to (B) DTIC and (C) Cisplatin chemotherapy treatment was reduced 
compared to control short hairpin scramble (shSCR) cells. Results show the average of three independent 
experiments ± SEM.
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Chemotherapy resistance is abrogated in cells with reduced expression of B7-H3. Interestingly, 
we observed 1.228-fold (SD ± 0.136265, p-value 0.004) higher B7-H3 expression in FEMX-V DTIC resistant 
(DR) cell line as compared to the sensitive parental cell line (Fig. 3A). Next, we investigated if reducing B7-H3 
expression could increase sensitivity to chemotherapy in cells with induced drug resistance. To this end, we used 
the FEMX-V DTIC resistant (DR) cell line stably transduced with shRNA to reduce the B7-H3 expression as 
previously described (Fig. 3A). Upon DTIC treatment, the ability of FEMX-V shB7-H3 DR cells to form colonies 
was reduced to the level of FEMX-V sensitive control shSCR cells (Fig. 3B). Similarly, in xenograft experiments 
(Fig. 3C) the tumor growth curves were similar for mice injected with FEMX-V shB7-H3 DR cells to that of mice 
injected with FEMX-V sensitive cells. These data reinforce the notion that reducing B7-H3 expression inde-
pendently abrogates the DTIC resistance of melanoma cells.
DUSP10 expression is increased in shB7-H3 cells, and correlates with lower p-p38 MAPK lev-
els. In attempts to reveal the molecular basis of the involvement of B7-H3 in the drug resistance of FEMX-V 
DR cells, we performed a comparative DNA microarray gene expression analysis on FEMX-V DR control 
(shSCR) and shB7-H3 cells. Top differentially expressed genes with log2 value ±1 and p-value less than 0.05 are 
listed in Supplementary Table 1. Interestingly, one of the up-regulated genes was the dual-specific phosphatase 
DUSP10 (log2 Ratio = 1.052, p-value = 0.000124284). DUSP10 is a MAP kinase phosphatase known to dephos-
phorylate and negatively regulate p38 MAPK9. Up-regulation of DUSP10 mRNA expression was validated by 
qPCR (Fig. 4A). Additionally, we observed up-regulation of DUSP10 in FEMX-I shB7-H3 cells, and to a less 
extent in MDA-MB-435, shB7-H3 cells (Fig. 4A). To test the involvement of DUSP10 in regulating p38 MAPK 
activation, we analyzed p38 MAPK activation status in shSCR and shB7-H3 FEMX-I cells treated with DTIC or 
cisplatin. Both drugs induced p38 MAPK activation. Notably, this activation was lower in shB7-H3 knockdown 
cells compared to control cells treated with DTIC or cisplatin (Fig. 4B,C), suggesting that B7-H3 protein expres-
sion is involved in p38 MAPK activation.
Increased drug sensitivity in shB7-H3 cells is reversed upon siRNA-induced down-regulation of 
DUSP10. To analyze if DUSP10 levels affected the sensitivity to chemotherapy, we knocked down DUSP10 
by siRNAs in shSCR and shB7-H3 FEMX-I cells. We observed a lower DTIC-induced activation of p38 MAPK in 
FEMX-I shB7-H3 cells compared to the shSCR cells, in consistence with higher DUSP10 expression (Figs 4A and 5A). 
Upon DUSP10 silencing, p38 MAPK activation was increased in both shSCR and shB7-H3 cells treated with 
DTIC. Moreover, the increased DTIC and cisplatin drug sensitivity achieved by B7-H3 knockdown was abrogated 
upon DUSP10 silencing (Fig. 5A,B and Supplementary Fig. 2). These results suggest that the increased chemosen-
sitivity displayed by shB7-H3 cells is mediated through increased expression of DUSP10.
Discussion
B7-H3 expression is associated with tumor progression and epigenetic regulatory activity in cutaneous mela-
noma22. B7-H3 expression in melanoma cells is also associated with sensitivity to various anti-cancer agents4, here 
including cisplatin. The mechanisms by which B7-H3 promotes drug resistance are largely unknown, although 
various pathways, such as JAK/Stat and PI3K/mTOR have been proposed to be involved20,21. In this study, we 
have identified the p38 MAPK pathway as a major effector of B7-H3-mediated resistance to chemotherapy and 
unveiled a novel B7-H3-associated regulation of p38 MAPK activation in melanoma cells. This regulation is 
mediated, at least in part, through the downregulation of the MAP kinase phosphatase DUSP10. Whether this 
B7-H3-DUSP10-p38 regulatory axis could be operative in other tumor types requires further studies. In this 
regard, p38 MAPK inactivation has been also observed in breast cancer cells upon knockdown of the B7-protein 
B7-H1/PD-L123.
Our results suggest that B7-H3 suppresses the expression of DUSP10 at the mRNA level, which in turn leads 
to higher p38 MAPK activation and increases tumor cell resistance to chemotherapy (Fig. 6). Thus, in our model, 
pharmacological inhibition of p38 MAPK would be beneficial and increase chemosensitivity of melanoma cells. It 
would be of interest to identify candidate DUSP10 transcription factors potentially repressed by B7-H3. DUSP10 
Figure 2. Tumor volume is reduced in vivo in shB7-H3 cells upon chemotherapy treatment. Mice were injected 
subcutaneously with 5 × 106 MDA-MB-435 melanoma control cells (shSCR) and cells having diminished B7-H3 
expression (shB7-H3). Upon B7-H3 knockdown, the relative tumor volume was reduced compared to control 
cells in response to (A) Dacarbazine (DTIC) (n = 20–22 in each group) and (B) Cisplatin (n = 5–6 in each 
group) chemotherapy treatment. Results show the relative tumor volume of the tumors ± SEM.
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is a stress-activated, JNK/p38-specific MKP widely expressed, reported to be involved in cancer progression 
and in the regulation of immune response9. Overexpression of DUSP10 in human colorectal cancer (CRC) cells 
resulted in reduced tumor formation in immune deficient mice, and high DUSP10 expression was associated with 
better survival in CRC patients24. Our in vitro and in vivo results also suggest an anti-oncogenic role for DUSP10 
in melanoma. In addition, our findings support the existence of a B7-H3-DUSP10-p38 axis important for cell 
proliferation which is independent of the immune system.
Interestingly, up-regulation of DUSP10 in prostate cancer cells correlated with inactivation of p38 MAPK and 
decreased production of the inflammatory cytokine IL-625, and DUSP10 was found to down-regulate the release 
of cytokines (IL-6 and TNF) by regulating p38 MAPK pathway in macrophages26. We have previously found 
B7-H3 expression to correlate with IL-8 secretion in melanoma cells5. Whether this phenomenon is mediated 
through DUSP10 needs further investigation.
In melanoma, activation of p38 MAPK has been associated with various cellular functions, including suppres-
sion of anti-tumor immune responses27, and resistance to chemotherapy28, and p38 MAPK inhibition has been 
found to suppress inflammation-induced metastasis29. Here, we observed activation of p38 MAPK in melanoma 
cells treated with either DTIC or cisplatin, indicating that these drugs affect cell proliferation through similar 
pathways. Inhibition of p38 MAPK is getting increased attention as a promising therapeutic approach in cancer30. 
Relevant to this, there are currently many clinical trials with various p38 MAPK inhibitors either alone or in com-
bination with other chemotherapeutic agents in different types of cancers31,32. p38 MAPK inhibition increased the 
sensitivity to cisplatin in colorectal cancer33, and to taxanes in breast cancer cells34. It would be interesting to test 
whether these mechanisms could be dependent on B7-H3 expression.
Figure 3. Reduced B7-H3 levels abolish dacarbazine (DTIC) resistance in DTIC resistant cells. FEMX-V cells 
with sensitivity (FEMX-V sensitive) or induced resistance to DTIC (FEMX-V DR), where knocked down for 
B7-H3. (A) Representative immunoblot of B7-H3 and α-tubulin expression in the four FEMX-V cell variants. 
(B) When these cells were subjected to DTIC treatment, little effect of DTIC was seen in the ability of drug 
resistant DR and DR shSCR cells to form colonies. FEMX-V DR shB7-H3 cells, however, displayed a reduced 
capacity to form colonies. Results show the average of two independent experiments ± SEM. (C) This effect was 
also seen in vivo, where FEMX-V shB7-H3 cells and FEMX-V sensitive cells displayed reduced relative tumor 
growth ± SEM compared to FEMX-V DR and FEMX-V DR shSCR cells (n = 7–8 in each group).
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Our findings support the idea that inhibiting B7-H3 may be a promising therapeutic concept in combina-
tion with chemotherapy. However, our in vitro and mouse xenograft models have limitations, and only reflect 
the B7-H3 tumor-intrinsic role. As B7-H3 is an immune checkpoint protein that prevents T cell activation, its 
inhibition could also affect immune function in the melanoma tumor microenvironment. Additional studies 
in immune competent mouse models would be necessary to assess the role of B7-H3 as an immune checkpoint 
protein and the potential of B7-H3 inhibition to promote both the anti-tumor immune response and sensitivity 
to chemotherapy in melanoma. Moreover, p38 MAPK signaling has been shown to induce the proliferation of 
regulatory T cells, thus dampening the immune response35. As B7-H3 expression correlates with the number of 
regulatory T cells36 and is known to exhibit a co-inhibitory signal on the immune system37, it would be interesting 
to investigate the activation of p38 MAPK by B7-H3 expression in immune competent models.
Materials and Methods
Cell cultures and silencing. FEMX-I and FEMX-V cell lines were established from a metastatic lymph 
node harvested from a melanoma patient operated at The Norwegian Radium Hospital38. FEMX-1 cells corre-
sponds to the first generation of brain metastasis, and FEMX-V cells corresponds to the fifth generation, estab-
lished by disaggregation, single cell formation and intraveneous re-injection in nude mice of the harvested cells 
as previously described39. MDA-MB-435 was acquired from ATCC. FEMX-V DTIC drug resistant (FEMX-V DR) 
cell lines were described previously40. B7-H3 knockdown in FEMX-V DR cells were made as reported for FEMX-I 
and MDA-MD-435 cells5, using HuSH 29mer shRNA constructs against B7-H3 (shB7-H3; sequence shRNA‐2, 
5′-TCGTGTGCTGGAGAAAGATCAAACAGAGC‐3′) and control plasmid pRS nontarget TR30003 (shSCR; 
sequence 5′‐GCACTACCAGAGCTAACTCAGATAGTACT‐3′) (both from Origene Technologies). All cells were 
grown in RPMI-1640 (Sigma Aldrich) with addition of 10% fetal bovine serum and 2 mM L-glutamine. DUSP10 
knockdown was performed by transfection of specific siRNAs using Lipofectamine 3000 (Thermo Fisher) fol-
lowing manufacturer’s protocol. DUSP10 siRNAs (siDUSP10 #1, SI03119998; siDUSP10 #2, SI03118178) were 
Figure 4. DUSP10 is induced in shB7-H3 cells and correlates with lower activation of p38 MAPK signaling 
by dacarbazine (DTIC) and cisplatin. (A) Mean fold change in gene expression of DUSP10 by qPCR of 
FEMX-V sensitive and DTIC resistant (DR), FEMX-I and MDA-MB-435 control (shSCR) and shB7-H3 cells. 
Representative immunoblot of phospho-p38 (p-p38), p38, and GAPDH levels in FEMX-I shSCR and shB7-H3 
melanoma cells treated with: (B) 5 μg/mL DTIC or (C) 10 μg/mL cisplatin treatment. Right panels in B and C, 
average of three independent immunoblot values of p-p38 levels divided by p38 levels ± SEM.
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from Qiagen (Thermo Scientific), and siNS (non-specific) siRNA (J-003104-13) was from Dharmacon. The final 
concentration of Lipofectamin3000 and siRNAs were 2 μl/mL and 50 nM, respectively. DUSP10 knockdown was 
verified 72 h post-transfection at mRNA level by RT-qPCR, as described below.
RNA isolation, DNA microarray and qPCR. The RNA was prepared for microarray analysis using the 
Illumina™ TotalPrep™ RNA amplification kit (Thermo Scientific) according to manufacturer’s protocol. The con-
centration of the samples was measured using NanoDrop spectrophotometer (Thermo Scientific) and the quality 
of the finished cRNA was assessed using the Bioanalyzer (Agilent Genomics). 1.5 µg biotin labeled cRNA was 
hybridized onto Illumina Human-6 Expression BeadChips (Illumina) using the Whole-Genome Gene Expression 
Direct Hybridization Assay (Illumina) according to manufacturer’s protocol. After scanning, the results were 
Figure 5. Reduced DUSP10 expression decreases chemosensitivity in shB7-H3 cells. (A) Left panel; 
Immunoblot analysis of phospho-p38 (p-p38), p38, and GAPDH expression upon DTIC treatment and right 
panel; average of three independent immunoblot values of p-p38 levels divided by p38 levels ± SEM in FEMX-I 
shSCR and shB7-H3 cells upon DUSP10 knockdown by siRNA. (B) Average proliferation of three independent 
experiments ± SEM of FEMX-I shSCR and shB7-H3 cells with DUSP10 knockdown and DTIC treatment as 
measured by the Incucyte FLR imaging system 72 h after treatment.
Figure 6. Schematic figure of how B7-H3 affects p38 MAPK signaling through modulation of DUSP10. In 
response to DTIC treatment, cells expressing B7-H3 have a lower level of DUSP10, which results in higher 
activation of p38 MAPK and resistance to chemotherapy. In cells with reduced B7-H3 levels, DUSP10 levels are 
higher and thus, p38 MAPK activation is lower, which leads to chemotherapy sensitivity. Upon reduction of 
DUSP10 levels, this sensitivity is eliminated.
7Scientific RepoRts |          (2019) 9:5839  | https://doi.org/10.1038/s41598-019-42303-w
www.nature.com/scientificreportswww.nature.com/scientificreports/
quality checked in Ilumina BeadStudio, and raw data were quantile normalized in log2 scale. The DNA microar-
ray analyses were performed at the Genomics core facility, Oslo University Hospital (OUH), Norway. Total RNA 
was isolated for RT followed by qPCR using QuantiTect Primers (Qiagen) for DUSP10 and HPRT as a housekeep-
ing gene as described previously in reference41.
Reagents, immunoblot and antibodies. Decarbazine (DTIC) (Lipomed GmbH) and cisplatin (Accord 
Healthcare) were used at indicated concentrations, during the indicated times. Dimethyl sulfoxide (DMSO) was 
used as a control. Whole cell protein extracts were prepared by total cell lysis and immunoblot was performed as 
described previously in reference4. Antibodies used for Western blotting were: B7-H3 (1:1000, AF1027, R&D), 
phosoho-p38 (#9211), p38 (#8690), GAPDH (#5174) (1:1000, Cell Signaling) and α-tubulin (1:50000, CP06, 
Millipore). Protein concentrations from total cell lysates were measured using Pierce® BCA Protein Assay Kit 
(Thermo Scientific). Immunoblot expression levels were quantified using ImageJ. Uncropped blots are provided 
in the Supplementary Information.
Cell proliferation and colony formation. To assess cell proliferation, 5000 cells/well were seeded on 
96-well plates and the cell confluence was measured every three hours by the IncuCyte FLR or IncuCyte Zoom 
imaging microscopes (Essen Biosciences). The cells were treated with indicated drugs at indicated concentrations 
21 h post-plating and were scanned for 72 h after adding the drugs. DMSO was added to control cells. For colony 
formation assays, 500 or 1000 cells/well were seeded on 6-well plates in media containing DMSO or indicated 
drugs. The cells were treated with drugs for 48 h, and plates were processed after 7 days. Colonies were counted 
after they were fixed with methanol and stained with 0.05% crystal violet.
In vivo studies. The in vivo studies were performed using female nude athymic (fox1nu) mice bred at the 
Department of Comparative Medicine, Institute for Cancer Research, OUH Radiumhospitalet. When the animals 
were 6–8 weeks of age, 5 × 106 cells were injected subcutaneously into both flanks of the nude mice. The treatment 
was initiated when the tumors were between 5–6 mm in diameter and consisted of a single treatment of 250 mg/
kg DTIC or 10 mg/kg Cisplatin administered intravenously. Solvent was administered for control mice. Tumors 
were measured twice a week and the tumor volume was calculated by the formula 0.5 × length × width2. The data 
is presented as the average ± standard error of the mean (SEM) of three independent experiments. All animals 
were kept according to regulations of the Norwegian Animal Welfare Act and the experiments were approved by 
the Norwegian Animal Research Authority and conducted according to the FELASA guidelines (FOTS applica-
tion number 1748 and 2499).
Statistical analysis. Data shows average values ± SEM for the average of three representative experiments 
and in vivo experiments. All experiments were performed in technical and biological triplicates, if not otherwise 
specified. Data was analyzed by Graphpad Prism 7.0 (Graphpad Software), where significance was calculated 
using two-tailed students t-test. P values of less than 0.05 were considered significant and were marked with an 
asterisk.
Conclusions
By using melanoma cells resistant to DTIC, we found that knocking down B7-H3 in these cells abolished the 
acquired resistance. These findings support the idea that inhibiting B7-H3 may be a promising therapeutic con-
cept in combination with chemotherapy. Furthermore, we observed a parallel upregulation of the mRNA levels 
of the dual-specific MAPK phosphatase DUSP10 in the B7-H3 knockdown cells. Consistently, lower p38 MAPK 
activation upon chemotherapy was observed in cells with reduced B7-H3 expression in parallel with increased 
sensitivity. Moreover, the increased sensitivity of B7-H3 knockdown cells was abolished by DUSP10 knockdown 
by siRNA. Taken together, we have discovered a novel mechanism that contributes to B7-H3-mediated drug 
resistance through attenuating DUSP10 expression thereby activating p38 MAPK in melanoma cells.
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